ライフサイエンスコーパス: prognosis

1 son's disease and are associated with poorer prognosis.

2 yocardial infarction is associated with poor prognosis.

3 aggressive malignancy with a uniformly poor prognosis.

4 which somatic alterations could not predict prognosis.

5 ment cost and decreased chances of favorable prognosis.

6 ressive disease progression and poor patient prognosis.

7 d no major impact on clinical management and prognosis.

8 neration biomarkers for cancer diagnosis and prognosis.

9 n indicator for neoadjuvant chemotherapy and prognosis.

10 molecular subgroups/subtypes, mutations, and prognosis.

11 is a candidate biomarker that may aid dengue prognosis.

12 aging guidelines and the potential impact on prognosis.

13 is a rare, but aggressive tumor with dismal prognosis.

14 mong patients considered to have a favorable prognosis.

15 n of miR-21 is correlated with poorer glioma prognosis.

16 ubset of HCC patients with a relatively poor prognosis.

17 V(max) approach differed in their iPET-based prognosis.

18 ing markers of stromal ecology would improve prognosis.

19 when counseling PXE patients on their visual prognosis.

20 y have been associated with sarcoma risk and prognosis.

21 imits surgical options and portends a dismal prognosis.

22 sected to determine subsequent treatment and prognosis.

23 and long-term complications leading to poor prognosis.

24 after a second IVIg course in GBS with poor prognosis.

25 on of RAC1 and RAC2 was associated with poor prognosis.

26 rcinomas characterized by comparatively poor prognosis.

27 pulmonary hypertension (PoPH) carries a poor prognosis.

28 nd their lower level is associated with poor prognosis.

29 ocular disorder associated with poor visual prognosis.

30 the kidney allograft is associated with poor prognosis.

31 -risk multiple myeloma have a poor long-term prognosis.

32 better inform patients on the evolution and prognosis.

33 f 3%-7% progressing to ARF, a marker of poor prognosis.

34 carcinomas (sRCC) are associated with dismal prognosis.

35 ressive; its sarcomatoid variants have worse prognosis.

36 ciated with hematologic neoplasms and varied prognosis.

37 cal challenge that generally portends a poor prognosis.

38 evels of ADO that correspond to poor patient prognosis.

39 ed compared with those with a better initial prognosis.

40 ocyte-derived biomarker of kidney health and prognosis.

41 with increased AVIL expression have a worse prognosis.

42 ne oxygenation has been associated with poor prognosis.

43 C is challenging to treat and carries a poor prognosis.

44 o have haematological malignancies with poor prognosis.

45 cancer progression and correlates with poor prognosis.

46 trongly with elevated CD73 activity and poor prognosis.

47 scitation outcomes were modified by baseline prognosis.

48 associated with DNA repair defects and poor prognosis.

49 itional bleeding or MIs resulted in a poorer prognosis.

50 [mRS]), and phenotypes associated with poor prognosis.

51 differentiation and thus be associated with prognosis.

52 essed in human OS and correlates with a poor prognosis.

53 y aggressive and associated with unfavorable prognosis.

54 their potential significance in chemotherapy prognosis.

55 f EAC and its impact on individual patients' prognosis.

56 ions show significant associations with poor prognosis.

57 of Ezh2, similar to ACC patients with a poor prognosis.

58 diabetes mellitus screening, diagnosis, and prognosis.

59 , unlike acute postinfectious GN, has a poor prognosis.

60 brain tumour with high invasiveness and poor prognosis.

61 ithelial tumor of the biliary tree with poor prognosis.

62 n signature, which were associated with poor prognosis.

63 ansplantation (alloSCT), and carries a grave prognosis.

64 ypes and inversely correlated with patients' prognosis.

65 with HCC, but also associated with poor HCC prognosis.

66 fter PEA remains a major determinant of poor prognosis.

67 ment of ER+ patients (n = 68) predicted poor prognosis.

68 rcinomas (RCCs) and carries a decidedly poor prognosis.

69 th RB1 loss in the primary tumor had a worse prognosis.

70 ligibility for disease-specific therapy, and prognosis.

71 ne correlate with high-risk disease and poor prognosis.

72 ic features with adult types but have better prognosis.

73 inal B-cell lymphoma and conferred excellent prognosis.

74 e most frequent primary bone tumor with poor prognosis.

75 where low levels of C7 associate with poorer prognosis.

76 ed colorectal cancer (CRC) have still a poor prognosis.

77 tively common cutaneous neoplasm with a poor prognosis.

78 is known about the short-term and long-term prognosis after a first stroke in low-income and middle-

79 limited, indolent disease, with an excellent prognosis after implant and capsule removal.

80 PDE5 inhibitors was associated with a better prognosis among male patients with colorectal cancer (CR

81 ed tolerance to antineoplastic therapy, poor prognosis and accelerated death, with no approved treatm

82 desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the

83 ubtype of pancreatic cancer that has a worse prognosis and greater metastatic potential than the more

84 This grouping drives prognosis and influences treatment.

85 Grade 4 glioma or GBM has poor prognosis and is the most aggressive grade of glioma.

86 orated quality of life (QOL), with uncertain prognosis and limited treatment options.

87 iopathic pulmonary fibrosis (IPF) has a poor prognosis and limited treatment options.

88 Contemporary data are lacking regarding the prognosis and management of left ventricular thrombus (L

89 that holds the potential to provide a better prognosis and overall quality of life for GBM patients.

90 s the clinical value of Alphabeta1-40 in CVD prognosis and patient risk stratification, and present t

91 ht be useful biomarkers in the estimation of prognosis and question of treatment.

92 ceiving personalized care and counselling on prognosis and recurrence risk.

93 ession level could serve as an indicator for prognosis and survival outcome in patients with AML.

94 o augment clinicians' capabilities in cancer prognosis and theragnosis by harnessing biological signa

95 ets, as well as a clearer picture of patient prognosis and therapeutic direction.

96 variants, enabling individualized diagnosis, prognosis and therapy selection.

97 sometimes complex associations with patient prognosis and treatment benefit.

98 tus (ERS) is a key molecular marker used for prognosis and treatment decisions.

99 I is a strong biomarker candidate to predict prognosis and treatment efficacy.

100 e prognostic and therapeutic goals for early prognosis and treatment of various brain maladies such a

101 cation of tumors are critical for subsequent prognosis and treatment planning.

102 inform the identification of biomarkers for prognosis and treatment response.

103 which somatic alterations could not predict prognosis, and a unique cohort LGG, for which SPM data w

104 Acute heart failure confers a worse prognosis, and although lung ultrasound (LUS) is recomme

105 of WBP2 as a biomarker for early detection, prognosis, and companion diagnostics in breast cancer.

106 t of IMD, comorbidities, hematologic disease prognosis, and future plans for chemotherapy or transpla

107 (HCC) is difficult to detect, carries a poor prognosis, and is one of few cancers with an increasing

108 ine as a cancer biomarker for the detection, prognosis, and management of cancer, as well as for moni

109 eatic ductal adenocarcinoma carries a dismal prognosis, and outcomes have improved little with modern

110 For optimal diagnosis, prognosis, and precision medicine, no single ruling tech

111 emerged as powerful tools for the diagnosis, prognosis, and prediction of treatment responses to impr

112 ecisions in relation to patient preferences, prognosis, and proportionality.

113 iated with treatment resistance, unfavorable prognosis, and the infiltration of pro-tumorigenic macro

114 PADI4 in human PDAC corresponds with poorer prognosis, and the serum of patients with PDAC has highe

115 Pancreatic cancer has a dismal prognosis, and there is no targeted therapy against this

116 ignificant with respect to diagnosis of LVH, prognosis, and treatment decisions.(C) RSNA, 2020.

117 clinical care across the cycle of diagnosis, prognosis, and treatment of disease.

118 multiple sclerosis diagnosis, assessment of prognosis, and treatment responses, in particular those

119 orts, despite implications for surveillance, prognosis, and treatment.

120 diac and vascular pathophysiology, to assess prognosis, and understand the role of endotying to direc

121 as a biomarker for melanoma progression and prognosis, and we showed that TTCC blockers reduce migra

122 rs, making them attractive for diagnosis and prognosis applications.

123 Course and prognosis are benign, visual acuity usually recovers.

124 as emerged as a promising approach in cancer prognosis as sequencing data becomes more easily and aff

125 fibers to be used as powerful biomarker for prognosis, as a tool to stratify patients for therapy or

126 izes to the omentum contributing to the poor prognosis associated with ovarian cancer.

127 Visual prognosis at the final follow up was consistent with the

128 a higher proportion that changed to a worse prognosis at the latest periodontal exam.

129 d significant positive correlation with poor prognosis beyond five years in both postmenopausal and p

130 e repair, all of which incrementally improve prognosis beyond foundational neurohormonal therapies.

131 et-based digital PCR constitutes a promising prognosis biomarker in COVID-19 patients.

132 or ECM has been associated with poor patient prognosis but the reason for this is not well understood

133 lymphoma, angiogenesis correlates with poor prognosis, but attempts to target established proangioge

134 ed novel insights on its pathophysiology and prognosis, but its use in AF-related stroke remains limi

135 We compared MI type, frequency, and prognosis by treatment assignment using both MI definiti

136 Teeth initially assigned to a poorer prognosis category had a higher proportion that changed

137 We examined the effect of HF development on prognosis compared with other cardiovascular or renal di

138 Notably one network, associated with poorer prognosis, comprises five up-regulated lncRNAs significa

139 Metastatic melanoma carries a poor prognosis despite modern systemic therapies.

140 r biochemical markers in body fluids for the prognosis, diagnosis and management of diseases, as well

141 Past studies revealed the prognosis differed between aneurysmal subarachnoid hemor

142 egative breast cancer (TNBC), which has poor prognosis due to frequent metastasis.

143 owever, patients with KIRC usually have poor prognosis due to limited biomarkers for early detection

144 egmentation methods can be used that predict prognosis equally well but give different optimal cutoff

145 ent on an ICU providing a description of how prognosis evolves over time.

146 t pairs of comorbidities could be a negative prognosis factor for the severity of disease for the SAR

147 We investigated the long-term prognosis following infection-related hospitalization.

148 Despite improvements in prognosis following myocardial infarction (MI), racial d

149 This paper provides new information on how prognosis following pancreatectomy for PDAC evolves over

150 novel therapeutic strategies to improve the prognosis for breast cancer patients.

151 e tumor center were associated with improved prognosis for cancer-specific survival (HR = 0.65, p < 0

152 The prognosis for couples with recurrent pregnancy loss is g

153 for those at risk, and to objectively guide prognosis for friends and family of affected individuals

154 ion of GABPB1-AS1 was correlated with a poor prognosis for HPV16-positive CC patients.

155 The long-term prognosis for malignant INS is poor, because micrometast

156 tients into discriminative groups to improve prognosis for overall survival (OS) and relapse free sur

157 The overall prognosis for pancreatic cancer remains dismal and poten

158 The prognosis for pancreatic ductal adenocarcinoma (PDAC) re

159 The prognosis for patients who undergo concurrent resection

160 The prognosis for patients with pancreatic cancer is extreme

161 eloped to assist in determining the clinical prognosis for SARS-CoV-2 pneumonia.

162 r cancer cells in the brain and confers poor prognosis for the patient.

163 ow-risk recurrence groups, and poor and good prognosis groups directly from the H&E tissue slides.

164 Teeth with initial poorer prognosis had a higher chance of being extracted compare

165 The bad prognosis, high rate of relapse and resistance against a

166 hematopoietic cell transplantation have poor prognosis, highlighting an unmet therapeutic need.

167 iomarker for both anti-PD-(L)1 treatment and prognosis; however, multiple challenges still hinder the

168 nts with cancer and are associated with poor prognosis; however, their role in transplantation is not

169 mrLNMs were associated with good prognosis (HR 0.50 (0.31-0.80)p= 0.004 for OS, 0.60 (0.4

170 d analyses of ChIP-seq, RNA-seq, and patient prognosis identified sphingosine kinase 1 (SPHK1) as a k

171 ssive malignancy with a dismal posttreatment prognosis-implicate XBP1s in promoting tumor vasculariza

172 SLC2A3 expression is associated with patient prognosis, implying an important role for the HIF/NICI/S

173 from diagnosis to treatment start (TDT) and prognosis in a large real-world data set from the German

174 Malnutrition is associated with poor prognosis in a wide range of illnesses.

175 d gene that is highly associated with a poor prognosis in acute myeloid leukemia (AML).

176 and radiotherapy and is associated with poor prognosis in advanced stage.

177 Higher GCS indicated better prognosis in all patients.

178 35-kDa isoform and its association with poor prognosis in cancers.

179 key factor influencing choice of therapy and prognosis in cervical and endometrial cancers; therefore

180 so did a systematic review of UIA prevalence/prognosis in cohorts with TIA/stroke.

181 tein levels of ERalpha, associates with poor prognosis in ER-positive breast cancer patients.

182 protein level is negatively associated with prognosis in GC patients, suggesting that UBE2T is a pro

183 ime and acted as a robust biomarker for poor prognosis in gliomas.

184 and SLC12A3 in tumours correlates with worse prognosis in KIRC patients, while higher expression of A

185 ed LDN (>10%) remarkably related with poorer prognosis in late stage patients.

186 ues and cell lines, and correlated with poor prognosis in lung cancer patients.

187 expression of JAK3 is correlated with poorer prognosis in melanoma patients.

188 nts, leading to TERT overexpression and poor prognosis in neuroblastoma, but TERT-associated oncogeni

189 ed risk of developing cancer as well as poor prognosis in patients with cancer.

190 tion stress markers was associated with poor prognosis in patients with HGSOC.

191 ssive hematological malignancy with a dismal prognosis in patients with resistant or relapsed disease

192 yopathy and is the major contributor to poor prognosis in patients with systemic amyloidosis.

193 associated T-cell infiltrate informs patient prognosis in primary Merkel cell carcinoma beyond the T-

194 k, rather than other factors known to affect prognosis in PWID.

195 ing no effect in the NOTCH2 subtype and poor prognosis in the MYD88 subtype.

196 sis formation, which is associated with poor prognosis in triple-negative breast cancer (TNBC).

197 ty and 91.9% specificity for predicting poor prognosis in women younger than 60 years.

198 Prognosis in young patients with breast cancer is genera

199 It carries a poor prognosis, in part because its pathogenesis is not well

200 Phenotypes of poor prognosis included ADEM-like relapses progressing to leu

201 Because clear communication of prognosis is an ethical mandate, more research is needed

202 ns, one of the most debilitating in terms of prognosis is heart failure.

203 tiation of antiretroviral therapy, and their prognosis is inferior to the immunological responders (I

204 Without therapy, prognosis is poor but treatments, typically immunosuppre

205 Our results suggest that prognosis is poor for patients with Shwachman-Diamond sy

206 LBCL) are limited, with no standard of care; prognosis is poor, with 4- to 6-month median survival.

207 erexpressed in human OC associated with poor prognosis, is essential for OC progression principally b

208 vide information about leukaemia biology and prognosis, it cannot distinguish which mutations occur i

209 causes of PH are heterogeneous, and patient prognosis may vary by etiologic subtype.

210 ng the two types of important data in cancer prognosis modeling and into lung cancer overall survival

211 Peak oxygen uptake, a primary determinant of prognosis, mortality and quality of life, is diminished

212 tic substrate appears to play a role in both prognosis (multiple sarcomeric variants) and the risk fo

213 ) with genetic manipulation, and the adverse prognosis of 14q-deleted ccRCC patients.

214 provided a hazard ratio for poor versus good prognosis of 3.84 (95% CI 2.72-5.43; p<0.0001) in the pr

215 critically ill patients to the diagnosis and prognosis of acute ischemic stroke, septic shock, lung i

216 ltimodal chemotherapy continues to limit the prognosis of acute lymphoblastic leukemia (ALL).

217 GPBB, CK-MB and cTnT for early diagnosis and prognosis of acute myocardial infarction (AMI) are prese

218 of family history of AD on the incidence and prognosis of AD and estimate the heritability and enviro

219 high G9a expression is associated with poor prognosis of CCA patients.

220 ces have dramatically improved the long-term prognosis of children and adolescents with inborn errors

221 The poorer prognosis of coronary artery disease in females compared

222 and DN, suggesting a potential biomarker for prognosis of DN.

223 The overall prognosis of filtering-associated endophthalmitis remain

224 endent diagnostic marker predicting the poor prognosis of HCC patients.

225 The prognosis of HCM-LVSD has reportedly been poor, but beca

226 r that is used for screening, diagnosis, and prognosis of HF.

227 Background The prognosis of hospitalized patients with severe coronavir

228 and indicates complicated treatment and bad prognosis of infections caused by such strains.

229 t pathways have been altered due to the poor prognosis of intubated patients and the risk of transmis

230 PLA(2)R1 "epitope spreading" determines the prognosis of membranous nephropathy.

231 th autologous stem cell transplantation, the prognosis of MM patients is still poor.

232 The adverse prognosis of myocardial injury in COVID-19 relates large

233 mation, is implicated in the progression and prognosis of ovarian cancer (OvCa).

234 The prognosis of patients with bulky nodal and metastatic PS

235 The aim of this project was to compare the prognosis of patients with ISM with that of patients wit

236 tions between pathologic fractures (PFs) and prognosis of patients with primary central high-grade os

237 tuf gene could help evaluation of the visual prognosis of patients.

238 prognostic implications, such as unfavorable prognosis of PAX3-FOXO1 fusion in alveolar rhabdomyosarc

239 owever, they still have a negative impact on prognosis of pneumonia patients, including higher mortal

240 y, we aimed to investigate the phenotype and prognosis of RTD patients with late-onset MN.

241 Information about prediction model of prognosis of SARS-CoV-2 infection is scarce.

242 rich in these fatty acids might improve the prognosis of STEMI.

243 the age-specific prevalence, predictors, and prognosis of symptomatic intracranial stenosis in a popu

244 The prognosis of the following groups (group 1: reverse LV r

245 The prognosis of those with PVCs is variable, with ongoing u

246 railty and acute ischaemia contribute to the prognosis of thrombolysis-treated AIS patients for sICH

247 n of imaging features may help in diagnosis, prognosis of, or treatment decision in cardiovascular, p

248 These antibodies could predict prognosis or be potential intervention targets to preven

249 ultivariable prediction model for Individual Prognosis Or Diagnosis) statement provides general recom

250 Due to its late diagnosis and dismal prognosis, pancreatic ductal adenocarcinoma (PDAC) is on

251 a key to therapeutic adaptation and improved prognosis, particularly for infections such as endocardi

252 is a deadly hematologic malignancy with poor prognosis, particularly in the elderly.

253 yroid cancer (ATC) is aggressive with a poor prognosis, partly because of the immunosuppressive micro

254 he literature and may be considered a poorer prognosis phenotype of neonatal-onset glaucoma.

255 complementary measures for the diagnosis and prognosis prediction of PTSD in recently traumatized ind

256 en using somatic alterations data for cancer prognosis prediction, pathway-level models are more inte

257 o limited biomarkers for early detection and prognosis prediction.

258 of significant ocular injury and with visual prognosis preservation.

259 sis helps in precise diagnosis of CN1 and in prognosis, prompt medical intervention and appropriate t

260 ly supported circulating, drug-resistant and prognosis-related lncRNA biomarkers; (ii) 11 418 somatic

261 FDA-approved method for the CTC-based cancer prognosis, relies on immunoaffinity interactions between

262 protein biomarkers for cancer diagnosis and prognosis remains a critical unmet clinical need.

263 Despite medical advancements, it's prognosis remains poor as many patients with heart failu

264 espite a potential benefit of PAH treatment, prognosis remains poor, and double-lung transplantation

265 Prognosis remains poor, despite the combined treatment o

266 studies showing good, intermediate, and poor prognosis, respectively.

267 (GBM) is a malignant brain tumor with a poor prognosis resulting from tumor resistance to anticancer

268 x, length of follow-up period, initial tooth prognosis, revised tooth prognosis, tooth type, and numb

269 of microbiome-based biomarkers in diagnosis, prognosis, risk profiling, and precision therapy require

270 Thus, CAAs predict cancer prognosis, shape tumour evolution, metastasis and drug r

271 e who showed a good treatment response had a prognosis similar to patients who were negative at basel

272 of risk estimation, diagnosis, treatment and prognosis strategies in the setting of sepsis and discus

273 ssed using the I(2) statistic and Quality in Prognosis Studies tool, respectively.

274 tenin-independent function of BCL9 in a poor-prognosis subtype of CRC tumors characterized by express

275 The worst-prognosis subtype was characterized by mesenchymal gene

276 l breast cancer and is associated with worse prognosis than other subtypes of breast cancer.

277 istently negative BDG tests present a better prognosis than the comparative group, probably due to a

278 (LV dominant and biventricular) had a worse prognosis than those with lone RV (p < 0.0001).

279 expressing high levels of ERK2 have a poorer prognosis than those with low ERK2-expressing tumors.

280 UTUCs) are rare, with poorer stage-for-stage prognosis than urothelial carcinomas of the urinary blad

281 ding cancer therapies, cancer stage specific prognosis, the kinetics of cancer recurrence, as well as

282 seems to negatively affect sleep quality and prognosis; therefore, identification of this activity mi

283 Additional advantages such as better disease prognosis thus allowing a more effective treatment, lowe

284 riod, initial tooth prognosis, revised tooth prognosis, tooth type, and number of teeth lost at the l

285 This document contains prognosis, treatment, and transplant recommendations for

286 te stable (MSS) samples demonstrated a clear prognosis value both for TCR abundance (HR = 0.39, 95% C

287 On survival analysis, a favorable prognosis was associated with opsoclonus, female sex, an

288 sis before 12 months of age, whereas a worse prognosis was associated with orbital involvement.

289 This suggests that patient prognosis was considered in ICU admission, reducing heal

290 The prognosis was rather poor for patients with HDV viremia

291 data and risk factors with regard to visual prognosis were analyzed with the help of the Statistical

292 These improvements in prognosis were most prominent from 2000 to 2004 to 2005

293 is an aggressive disease with extremely poor prognosis when treated with conventional chemotherapy.

294 ted immunoregulation is associated with poor prognosis, whereas early innate signaling and Th1-skewed

295 ma sodium was uniformly associated with good prognosis, whereas in HIV-uninfected patients the associ

296 cutaneous squamous cell carcinoma have poor prognosis with conventional systemic therapy.

297 lly advanced pancreatic cancer have a dismal prognosis, with a median overall survival (OS) of 12-14

298 cess issues) and were associated with a poor prognosis, with a very high in-hospital and late death r

299 only the HVPG responders (n = 32) had a good prognosis, with lower rebleeding risk and better surviva

300 etic alterations characteristic of favorable prognosis-with many tumors falling into multiple categor